A novel bioresorbable drug-eluting polycaprolactone (PCL) mesh scaffold was developed, utilizing a solvent-cast additive manufacturing technique, to promote therapy of muscle injury. The degradation rate and mechanical properties strength of the PCL mesh were characterized after immersion in a buffer solution for different times. The in vitro release characteristics of vancomycin, ceftazidime, and lidocaine from the prepared mesh were evaluated using a high-performance liquid chromatography (HPLC) assay. In addition, the in vivo efficacy of PCL meshes for the repair of muscle injury was investigated on a rat model with histological examinations. It was found that the additively manufactured PCL meshes degraded by 13% after submission in buffered solution for four months. All PCL meshes with different pore sizes exhibited greater strength than rat muscle and survived through 10,000 cyclic loadings. Furthermore, the meshes could offer a sustained release of antibiotics and analgesics for more than 3 days in vitro. The results of this study suggest that drug-loaded PCL mesh exhibits superior ability to pure PCL mesh in terms of effectively promoting muscle repair in rat models. The histological assay also showed adequate biocompatibility of the resorbable meshes. The additively manufactured biodegradable drug-eluting meshes may be adopted in the future in humans for the therapy of muscle injuries.

中文翻译：

---

用于治疗肌肉损伤的新型生物可吸收药物洗脱网支架

利用溶剂铸造增材制造技术，开发了一种新型生物可吸收药物洗脱聚己内酯（PCL）网状支架，以促进肌肉损伤的治疗。在缓冲溶液中浸泡不同时间后，表征了 PCL 网的降解率和机械性能强度。使用高效液相色谱 (HPLC) 测定法评估了万古霉素、头孢他啶和利多卡因从制备的网中的体外释放特性。此外，通过组织学检查在大鼠模型上研究了 PCL 网片修复肌肉损伤的体内功效。结果发现，增材制造的 PCL 网格在缓冲溶液中放置四个月后降解了 13%。所有具有不同孔径的 PCL 网都表现出比大鼠肌肉更大的强度，并且能够承受 10,000 次循环负载。此外，网状物可以在体外持续释放抗生素和镇痛药超过三天。本研究结果表明，载药PCL网片在有效促进大鼠模型肌肉修复方面表现出优于纯PCL网片的能力。组织学测定还显示可吸收网片具有足够的生物相容性。增材制造的可生物降解药物洗脱网将来可能会用于人体肌肉损伤的治疗。